The trick here is to spot the one azole that cannot treat mucormycosis - that is voriconazole.
Mucorales are intrinsically resistant to voriconazole. Clinically this is more than a footnote: widespread voriconazole prophylaxis in neutropenic and transplant patients is a well-documented cause of breakthrough mucormycosis, because it suppresses Aspergillus while leaving the Mucorales niche open.
Effective options follow a clear hierarchy. Liposomal amphotericin B is the backbone of therapy, given alongside surgical debridement and reversal of the host risk factor. For step-down or salvage, the broad-spectrum azoles posaconazole and isavuconazole both retain anti-Mucorales activity (isavuconazole carries a specific FDA approval).
\[\boxed{\text{No anti-Mucorales activity} \Rightarrow \text{Voriconazole}}\]